These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34445786)

  • 1. Diabetic Kinome Inhibitors-A New Opportunity for β-Cells Restoration.
    Pucelik B; Barzowska A; Dąbrowski JM; Czarna A
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.
    Kumar K; Suebsuwong C; Wang P; Garcia-Ocana A; Stewart AF; DeVita RJ
    J Med Chem; 2021 Mar; 64(6):2901-2922. PubMed ID: 33682417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration.
    Ackeifi C; Wang P; Karakose E; Manning Fox JE; González BJ; Liu H; Wilson J; Swartz E; Berrouet C; Li Y; Kumar K; MacDonald PE; Sanchez R; Thorens B; DeVita R; Homann D; Egli D; Scott DK; Garcia-Ocaña A; Stewart AF
    Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.
    Abdolazimi Y; Zhao Z; Lee S; Xu H; Allegretti P; Horton TM; Yeh B; Moeller HP; Nichols RJ; McCutcheon D; Shalizi A; Smith M; Armstrong NA; Annes JP
    Endocrinology; 2018 Sep; 159(9):3143-3157. PubMed ID: 29514186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
    Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
    J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DYRK1A inhibitors for disease therapy: Current status and perspectives.
    Liu T; Wang Y; Wang J; Ren C; Chen H; Zhang J
    Eur J Med Chem; 2022 Feb; 229():114062. PubMed ID: 34954592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of DYRK1A Stimulates Human β-Cell Proliferation.
    Dirice E; Walpita D; Vetere A; Meier BC; Kahraman S; Hu J; Dančík V; Burns SM; Gilbert TJ; Olson DE; Clemons PA; Kulkarni RN; Wagner BK
    Diabetes; 2016 Jun; 65(6):1660-71. PubMed ID: 26953159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
    Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
    J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.
    Liu YA; Jin Q; Ding Q; Hao X; Mo T; Yan S; Zou Y; Huang Z; Zhang X; Gao W; Wu TY; Li C; Bursalaya B; Di Donato M; Zhang YQ; Deaton L; Shen W; Taylor B; Kamireddy A; Harb G; Li J; Jia Y; Schumacher AM; Laffitte B; Glynne R; Pan S; McNamara P; Molteni V; Loren J
    ChemMedChem; 2020 Aug; 15(16):1562-1570. PubMed ID: 32613743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system.
    Rosselot C; Li Y; Wang P; Alvarsson A; Beliard K; Lu G; Kang R; Li R; Liu H; Gillespie V; Tzavaras N; Kumar K; DeVita RJ; Stewart AF; Stanley SA; Garcia-Ocaña A
    Sci Transl Med; 2024 Jul; 16(755):eadg3456. PubMed ID: 38985854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.
    Ackeifi C; Swartz E; Kumar K; Liu H; Chalada S; Karakose E; Scott DK; Garcia-Ocaña A; Sanchez R; DeVita RJ; Stewart AF; Wang P
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A natural DYRK1A inhibitor as a potential stimulator for β-cell proliferation in diabetes.
    Zheng M; Zhang Q; Zhang C; Wu C; Yang K; Song Z; Wang Q; Li C; Zhou Y; Chen J; Li H; Chen L
    Clin Transl Med; 2021 Jul; 11(7):e494. PubMed ID: 34323401
    [No Abstract]   [Full Text] [Related]  

  • 15. DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis.
    Barzowska A; Pucelik B; Pustelny K; Matsuda A; Martyniak A; Stępniewski J; Maksymiuk A; Dawidowski M; Rothweiler U; Dulak J; Dubin G; Czarna A
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
    Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
    J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
    Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
    FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel factors modulating human β-cell proliferation.
    Shirakawa J; Kulkarni RN
    Diabetes Obes Metab; 2016 Sep; 18 Suppl 1(Suppl 1):71-7. PubMed ID: 27615134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
    Henderson SH; Sorrell F; Bennett J; Fedorov O; Hanley MT; Godoi PH; Ruela de Sousa R; Robinson S; Ashall-Kelly A; Hopkins Navratilova I; Walter DS; Elkins JM; Ward SE
    J Med Chem; 2021 Aug; 64(15):11709-11728. PubMed ID: 34342227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DYRK1A kinase inhibitors with emphasis on cancer.
    Ionescu A; Dufrasne F; Gelbcke M; Jabin I; Kiss R; Lamoral-Theys D
    Mini Rev Med Chem; 2012 Nov; 12(13):1315-29. PubMed ID: 23016545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.